Pharmacological profiles of a novel protein tyrosine phosphatase 1B inhibitor, JTT-551

Diabetes, Obesity and Metabolism

Volumn 12, Issue 4, 2010, Pages 299-306

  Fukuda, S ^a   Ohta, T ^a   Sakata, S ^a   Morinaga, H ^a   Ito, M ^a   Nakagawa, Y ^a   Tanaka, M ^a   Matsushita, M ^a  

^a JAPAN TOBACCO INC   (Japan)

Author keywords

Db db mice; Glucose uptake; JTT 551; Ob ob mice; Protein tyrosine phosphatase1B

Indexed keywords

ANTIDIABETIC AGENT; CHOLESTEROL; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN RECEPTOR; JTT 551; MONOSODIUM [[[5 (1,1 DIMETHYLETHYL)THIAZOL 2 YL]METHYL [[[4 [4 [4 (1 PROPYLBUTYL)PHENOXY]METHYL]PHENYL]THIAZOL 2 YL]METHYL]AMINO]ACETATE; PIOGLITAZONE; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE 1B INHIBITOR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DRUG ACTIVITY; DRUG SCREENING; ENZYME INHIBITION; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; LIVER; MALE; MOUSE; MYOBLAST; NONHUMAN; PROTEIN PHOSPHORYLATION; RAT; SINGLE DRUG DOSE;

EID: 77954378714     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2009.01162.x     Document Type: Article

References (38)

1. Stein CJ, Colditz GA. The epidemic of obesity. J Clin Endocrinol Metab 2004, 89:2522-2525.
2. Wild S, Roglic G, Green A. Global prevalence of diabetes: estimates for the year 2000 and projection for 2030. Diabetes Care 2004, 27:1047-1053.
3. Fonseca V. Clinical significance of targeting postprandial and fasting hyperglycemia in managing type 2 diabetes mellitus. Curr Med Res Opin 2003, 19:635-641.
4. Saltiel AR. New perspectives into the molecular pathogenesis and treatment of type 2 diabetes. Cell 2001, 104:517-529.
5. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001, 414:782-787.
6. Ahrén B. Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes. Nature 2009, 8:369-385.
7. Grieve DJ, Cassidy RS, Green BD. Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control? Br J Pharmacol 2009, 157:1340-1351.
8. Saltiel AR, Kahn CR. Insulin signaling and the regulation of glucose and lipid metabolism. Nature 2001, 414:799-806.
9. Pessin JE, Saltiel AR. Signaling pathways in insulin action: molecular targets of insulin resistance. J Clin Invest 2000, 106:165-169.
10. Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest 2000, 106:171-176.
11. Tonks NK, Neal BG. Combinatorial control of the specificity of protein tyrosine phosphatases. Curr Opin Cell Biol 2001, 13:182-195.
12. Wu X, Hardy VE, Joseph JI. Protein-tyrosine phosphatase activity in human adipocytes is strongly correlated with insulin-stimulated glucose uptake and is a target of insulin-induced oxidative inhibition. Metabolism 2003, 52:705-712.
13. Kennedy BP, Ramachandran C. Protein tyrosine phosphatase-1B in diabetes. Biochem Pharmacol 2000, 60:877-883.
14. Ukkola O, Santaniemi M. Protein tyrosine phosphatase 1B: a new target for the treatment of obesity and associated co-morbidities. J Intern Med 2002, 251:467-475.
15. Elchebly M, Payette P, Michaliszyn E. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase 1B gene. Science 1999, 283:1544-1548.
16. Klaman LD, Boss O, Peroni OD. Increased energy expenditure, decreased adiposity, and tissue-specific insulin sensitivity in protein-tyrosine phosphatase 1B-deficient mice. Mol Cell Biol 2000, 20:5479-5489.
17. Ahmad F, Azevedo JL, Cortright R. Alterations in skeletal muscle protein-tyrosine phosphatase activity and expression in insulin-resistant human obesity and diabetes. J Clin Invest 1997, 100:449-458.
18. Cheung A, Kusari J, Jansen D. Marked impairment of protein tyrosine phosphatase 1B activity in adipose tissue of obese subjects with and without type 2 diabetes mellitus. J Lab Clin Med 1999, 134:115-123.
19. Zinker BA, Rondinone CM, Trevillyan JM. PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice. Proc Natl Acad Sci USA 2002, 99:11357-11362.
20. Rondinone CM, Trevillyan JM, Clampit J. Protein tyrosine phosphatase 1B reduction regulates adiposity and expression of genes involved in lipogenesis. Diabetes 2002, 51:2405-2411.
21. Pellegrini MC, Liang H, Mandiyan S. Mapping the subsite preferences of protein tyrosine phosphatase PTP-1B using combinatorial chemistry approaches. Biochemistry 1998, 37:15598-15606.
22. Hayes N, Biswas C, Strout HV. Activation by protein synthesis inhibitors of glucose transport into L6 muscle cell. Biochem Biophys Res Commun 1993, 190:881-887.
23. Ide T, Tsunoda M, Mochizuki T. Enhancement of insulin signaling through inhibition tissue lipid accumulation by activation of peroxisome proliferator-activated receptor (PPAR) α in obese mice. Med Sci Monit 2004, 10:BR388-BR395.
24. Byon JC, Kusari AB, Kusari J. Protein-tyrosine phosphatase-1B acts as negative regulator of insulin signal transduction. Mol Cell Biochem 1998, 182:101-108.
25. Goldstein BJ, Bittner-Kowalczyk A, White MF. Tyrosine dephosphorylation and deactivation of insulin receptor substrate-1 by protein-tyrosine phosphatase 1B. Possible facilitation by the formation of a ternary complex with the Grb2 adaptor protein. J Biol Chem 2000, 275:4283-4289.
26. Liu G, Xin Z, Liang H. Selective protein tyrosine phosphatase 1B inhibitors: targeting the second phosphotyrosine binding site with non-carboxylic acid-containing ligands. J Med Chem 2003, 46:3437-3440.
27. Bourdeau A, Dubé N, Tremblay ML. Cytoplasmic protein tyrosine phosphatases, regulation and function: the roles of PTP1B and TC-PTP. Curr Opin Cell Biol 2005, 17:203-209.
28. You-Ten KE, Muise ES, Itie A. Impaired bone marrow microenvironment and immune function in T cell protein tyrosine phosphatase-deficient mice. J Exp Med 1997, 186:683-693.
29. Yamada H, Kishihara K, Kong YY. Enhanced generation of NK cells with intact cytotoxic function in CD45 exon 6-deficient mice. J Immunol 1996, 157:1523-1528.
30. Wang Q, Khayat Z, Kishi K. GLUT4 translocation by insulin in intact muscle cells: detection by a fast and quantitative assay. FEBS Lett 1998, 427:193-197.
31. Noda S, Kishi K, Yuasa T. Overexpression of wild-type Akt1 promoted insulin-stimulated p70S6 kinase (p70S6k) activity and affected GSK3 beta regulation, but did not promote insulin-stimulated GLUT4 translocation or glucose transport in L6 myotubes. J Med Invest 2000, 47:47-55.
32. Cheon HG, Kim SM, Yang SD. Discovery of protein tyrosine phosphatase-1B inhibitor, KR61639: potential development as an antihyperglycemic agent. Eur J Pharmacol 2004, 485:333-339.
33. Erbe DV, Wang S, Zhang YL. Ertiprotafib improves glycemic control and lowers lipids via multiple mechanisms. Mol Pharmacol 2005, 67:69-77.
34. Arakawa K, Ishihara T, Aoto M. Actions of novel antidiabetic thiazolidinedione, T-174, in animal models of non-insulin-dependent diabetes mellitus (NIDDM) and in cultured muscle cells. Br J Pharmacol 1998, 125:429-436.
35. Iwata M, Haruta T, Usui I. Poglitazone ameliorates tumor necrosis factor-α-induced insulin resistance by a mechanism independent of adipogenic activity of peroxisome proliferator-activated receptor-γ. Diabetes 2001, 50:1083-1092.
36. Chen D, Wang MW. Development and application of rodent models for type 2 diabetes. Diabetes Obes Metab 2005, 7:307-317.
37. Shibata T, Matsui K, Nagao K. Pharmacological profiles of a novel oral antidiabetic agent, JTT-501, an isoxazolidinedione derivative. Br J Pharmacol 1999, 364:211-219.
38. Delibegovic M, Zimmer D, Kauffman C. Liver-specific deletion of protein-tyrosine phosphatase 1B (PTP1B) improves metabolic syndrome and attenuates diet-induced endoplasmic reticulum stress. Diabetes 2009, 58:590-599.